When one company's drug fails in a class, investors often punish the whole class because the science itself is in doubt — not just one company's execution. Novartis' flop suggests lowering Lp(a) may not translate into fewer heart attacks, which is the exa

Verdict: right mechanism, no trigger — watch-list only

**Verdict: an interesting thesis, but there is no trade here yet.** The idea argues that Novartis' Lp(a) trial failure (per the CNBC report published 2026-09-08) re-prices the whole drug class, and the mechanism is credible — but the fundamentals argue the market is pricing companies, not molecules: AMGN's June 2026 quarter showed revenue up 16.7% to $10.05B with free cash flow up 136% to $3.5B, and LLY grew revenue 16.0% to $23.0B even as net margin compressed from 37.4% to 30.9%. The strongest point against the short is that these mega-cap compounders with rising dividends (AMGN $9.94 trailing, LLY growing its payout 15.3% a year) attract dip buyers fast. The strongest point for it is the sentiment mechanism plus net insider open-market selling in both names for the June 30 period (roughly $2.1M net sold at AMGN across 13 holders and $2.9M at LLY across 21 holders). Critically, the entry rules never triggered across 1,236 daily bars, and the trend condition as compiled requires a 50-day average to cross below zero — an impossible condition — so the parameter review returned no robust setup; the research author has requested a bounded expanded search. **Conviction breakdown:** thesis support 55, trade readiness 20, risk quality 35, trigger proximity 20, fundamentals trend 30. What would flip the verdict: a re-parameterized, validated trigger combined with AMGN's RSI breaking below 48 or a close under the $430 support would turn this from watch-list to actionable.

Trade now: the entry gates are not met — LLY momentum is already there, the trend condition is not

Nothing is actionable today, and that is the honest headline. The strategy is a confirmation-then-short setup on Amgen and Lilly following the Novartis Lp(a) failure, per the idea's thesis, and it waits for price to confirm below trend with weak momentum before any position is opened. Right now the market is not there: **AMGN closed at $437.23** with an RSI of 55.4 — above the 48 ceiling the momentum condition requires, so that leg needs to fall another 7.4 points before it is even in range. **LLY closed at $1,149.36** and is the closer of the two: its RSI is 32.3, already below the 48 threshold, but the trend-confirmation leg is nowhere near triggered. Be aware of one mechanical problem in the compiled rules: the trend condition as written requires the 50-day moving average to cross below zero — something an equity price series can never do. AMGN's 50-day average sits at $397.02 and LLY's at $1,188.64. Because no robust setup was established for this idea, we cannot hand you a substitute trigger with confidence. What "wait" means concretely: no position in either name today; watch for AMGN's RSI to reach at or below 48 and for a viable trend threshold to be established before any short is considered. Risk framing in price terms while we wait: AMGN's nearest support is $430 and resistance is $440, with the stock just 1.6% below its range high — a level that argues against chasing a short here even if the gates were open. LLY is 10.2% below its range high with RSI already washed out; a bounce from here would invalidate the near-term bearish momentum case. Both names show net insider open-market selling into the June 30 filing period (about -$2.1M for AMGN across 13 holders, about -$2.9M for LLY across 21), which is directionally consistent with the bearish thesis but is confirmation context, not a trigger.

The bull case: two cash machines that a class-effect scare has not touched

### The fundamentals argue the market is pricing companies, not molecules The idea shorts Amgen and Eli Lilly on the theory that Novartis' Lp(a) setback poisons sentiment for the whole class. But look at what the latest reported quarter actually says. Amgen's June 2026 quarter (period ended 2026-06-30) showed revenue of $10.05B, up 16.7% from the prior quarter, with operating margin expanding from 30.9% to 35.0% and net income up 30.6% to $2.4B. Free cash flow jumped 136% sequentially to $3.5B, and leverage improved sharply — debt-to-equity fell 21.4% from 5.65 to 4.44. That is a company deleveraging on the back of accelerating cash generation, the opposite of the balance-sheet stress a sentiment short would want to lean on. Lilly's picture is even stronger on the top line. Its most recent fiscal year closed with Q4 2025 revenue of $19.3B, up 42.5% year over year — sitting at the 74th percentile of 752 Health Care peers — and the June 2026 quarter grew revenue another 16% sequentially to $23.0B. Gross margin hit 85.8% in that latest quarter, placing the company near the top of its sector. The demand engine behind these stocks (obesity, cardiometabolic franchises) is not what the Novartis trial tested; the thesis conflates a shared scientific mechanism with shared commercial exposure. Both companies also have dividend tracks that signal confidence and anchor long holders who must be shaken out for a sentiment short to work. Amgen has paid roughly $9.94 per share over the trailing twelve months with about 5.9% annual dividend growth, and Lilly has grown its payout 15.3% per year, most recently at $1.73 per quarter (ex-date 2026-08-14). Lilly's operating cash flow doubled sequentially to $10.7B in the June 2026 quarter. A stock with a rising dividend and expanding free cash flow tends to attract dip buyers quickly, which is precisely the counterforce the bearish idea needs…

Scores

• Conviction score breakdown: 32
• Thesis support: 55
• Trade readiness: 20
• Risk quality: 35
• Trigger proximity: 20
• Fundamentals trend: 30

Watch items

• AMGN — RSI (14)
• AMGN — 50-day moving average vs zero (pending re-parameterization)
• AMGN — Close vs nearest support
• LLY — RSI (14)
• LLY — 50-day moving average vs zero (pending re-parameterization)
• LLY — Close vs pivot levels
• AMGN — Quarterly revenue momentum (next print ~late Oct 2026)
• LLY — Net margin (next print ~early Nov 2026)
• AMGN — Insider net open-market activity (next filing cycle)
• LLY — Insider net open-market activity (next filing cycle)